Literature DB >> 19167016

Does the endogenous opiate system play a role in the Restless Legs Syndrome? A pilot post-mortem study.

Arthur S Walters1, William G Ondo, Wen Zhu, Weidong Le.   

Abstract

Opioids are an effective treatment for the signs and symptoms of Restless Legs Syndrome (RLS) and the signs and symptoms of RLS return when the opiate receptor blocker naloxone is given to opioid treated RLS patients in a blinded fashion. These data suggest that the opioid effect is specific to the opiate receptor in RLS and implicate the endogenous opioid system with its enkephalins and endorphins in the pathogenesis of RLS. We therefore measured Beta endorphin, Met-enkephalin and Leu-enkephalin levels in thalamus and substantia nigra of RLS patients (5 F - avg age 80.2 years) compared to controls (5 F, 1 M - avg age 76.3 years). One half of each brain was fixed in paraformaldehyde (PFA) in phosphate buffered saline (PBS) for pathologic evaluation and paraffin sections were stained with antibodies. Cell numbers were counted in a blinded fashion. In the thalamus, there were reductions of Beta-endorphin and Met-enkephalin positive cells by 37.5% (p=.006, effect size 2.16) and 26.4% (p=.028, effect size 1.58), respectively, in RLS patients compared to controls. There was no difference in Leu-enkephalin in the thalamus or changes in Beta endorphin, Met-enkephalin, Leu-enkephalin or Tyrosine Hydroxylase, the rate limiting step for dopamine synthesis, in the substantia nigra. Although one of the main hypotheses for pathogenesis has been that there is a dopaminergic hypofunction in RLS, this lack of decrease in Tyrosine Hydroxylase in substantia nigra is consistent with previously published post-mortem data in RLS. With Bonferroni correction, the decrease in thalamic Beta endorphin remained significant (p= .006 x 7= .042). These results suggest that there may be altered central processing of pain in RLS and these data further implicate the endogenous opioid system in the pathogenesis of RLS. The mu opiate receptor subtype may be involved in the pathogenesis of RLS as it is the target of Beta-endorphin and Met-enkephalin but not Leu-enkephalin. However, these results should be viewed as only preliminary and more advanced techniques such as stereology should be employed in future post-mortem studies. In addition, other opioid rich areas need to be explored as well as areas implicated in the pathogenesis of RLS such as the red nucleus and raphe nucleus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19167016     DOI: 10.1016/j.jns.2008.12.022

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  28 in total

Review 1.  Therapeutic Utility of Opioids for Restless Legs Syndrome.

Authors:  Susan E Mackie; John W Winkelman
Journal:  Drugs       Date:  2017-08       Impact factor: 9.546

Review 2.  Substance of abuse and movement disorders: complex interactions and comorbidities.

Authors:  Andres Deik; Rachel Saunders-Pullman; Marta San Luciano
Journal:  Curr Drug Abuse Rev       Date:  2012-09

3.  Restless legs syndrome: pathophysiology and treatment.

Authors:  William G Ondo
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

4.  Alterations in pain responses in treated and untreated patients with restless legs syndrome: associations with sleep disruption.

Authors:  Robert R Edwards; Phillip J Quartana; Richard P Allen; Seth Greenbaum; Christopher J Earley; Michael T Smith
Journal:  Sleep Med       Date:  2011-05-12       Impact factor: 3.492

5.  Mu opioid receptor knockout mouse: Phenotypes with implications on restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Erica L Unger; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  J Neurosci Res       Date:  2020-05-19       Impact factor: 4.164

6.  Pharmacological Management of Restless Legs Syndrome and Periodic Limb Movement Disorder in Children.

Authors:  Geoffrey Rulong; Thomas Dye; Narong Simakajornboon
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

7.  Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep.

Authors:  Richard P Allen; Peter B Barker; Alena Horská; Christopher J Earley
Journal:  Neurology       Date:  2013-04-26       Impact factor: 9.910

Review 8.  [Restless legs syndrome and nocturnal leg pain : Differential diagnosis and treatment].

Authors:  M Hornyak; K Stiasny-Kolster; S Evers; S Happe
Journal:  Schmerz       Date:  2011-09       Impact factor: 1.107

9.  Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  Behav Brain Res       Date:  2019-07-31       Impact factor: 3.332

Review 10.  Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology.

Authors:  Richard P Allen
Journal:  Sleep Med Clin       Date:  2015-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.